Team news

The team is a part of the PIA-3 awardees as a participant in the IMCBio graduate school

The Graduate School project “Integrative Molecular and Cellular Biology”, IMCBio selected in the call Programme d’investissements d’avenir

 

Based on a strategic clustering of Strasbourg assets in molecular and cellular biology from the three laboratories of excellence (LabEx), namely INRT (IGBMC), MitoCross (GMGM, IBMP, IBMC(ARN)) and NetRNA (IBMC (ARN, RIDI), IBMP), and with the support of cutting-edge technological tools such as the four national infrastructures in health biology (INBS) CELPHEDIA/PHENOMIN, FRISBI, France Génomique and Ingestem, together with the equipment of excellence (EquipEx) I2MC, the Graduate School (EUR) Integrative Molecular and Cellular Biology (IMCBio) project was selected on Tuesday, October 24, as part of the Programme d’investissements d’avenir (PIA3). This unprecedented training project is one of the four EUR winners supported by the University of Strasbourg, which has been allocated €25,717,000 for all of these projects.

 

Through additional internships in laboratories, complementary training modules at Master level, summer schools and a high-level training program for doctoral studies, the EUR IMCBio aims to attract students with a strong motivation for research and to train future researchers to work at the interfaces of Biology. With the joint support of the University of Strasbourg (Faculty of Life Sciences and Doctoral School of Life and Health), the CNRS and Inserm, this project, which is based on the graduate school model, has a triple ambition to strongly link training to research, to enhance the thematic strengths of the Strasbourg site and also to contribute to its international influence.

 

The third PIA call, which will fund this project, aims to structure the French higher education and research landscape and aims to offer university sites the opportunity to enhance the impact and international attractiveness of their research and training in one or more scientific fields. In the context of the EUR, this structuring involves bringing together master's and doctoral programs backed by one or more high-level research laboratories. Out of 195 projects submitted, 29 winners from this first call of the PIA3, amounting to €216 million over ten years, were jointly announced by the Ministry of Higher Education, Research and Innovation and the Commissioner General for Investment, stating that they had followed the advice of an international jury.

 

Contacts:

Internet site : IMCBio

Project Director: Bertrand Séraphin, Research Director, CNRS

Co-director of the project: Nicolas Matt, Senior Lecturer, University of Strasbourg

LabEx representatives: INRT (Bertrand Séraphin), MitoCross (Ivan Tarassov), NetRNA (Pascale Romby)

Centre de référence de maladies rares.

L'équipe fait dorénavant partie du centre de référence de maladies rares de Strasbourg, labelisé par le Ministère de la Santé en 2017.

LabEx MitoCross 2012-2020

Le projet Laboratoires d’Excellence (LabEx) Investissement d’Avenir vise à soutenir des projets scientifiques phare portés par des équipes de recherche et des laboratoires au meilleur niveau international. Les résultats de l’appel à projet de la 2ème vague ont été annoncés le 14 Février et mettent à l’honneur un consortium de 6 équipes Strasbourgeoises (UMR 7167 GMGM, UPR 2357 IBMP et UPR 9002 ARN), avec pour élément féderateur la mitochondrie. L'objectif global du consortium MitoCross est d'approfondir les connaissances et mécanismes moléculaires fins gouvernant la biogenèse des mitochondries, leur fonctionnement et leur communication avec les autres compartiments cellulaires. En exploitant des modèles d'étude différents que sont la levure, les plantes et l'homme, les nouvelles connaissances acquises permettront de développer des outils innovants en termes biotechnologique et biomédical.

 

 

Pour en savoir plus

Genomes expression and cross-talk in mitochondrial function and dysfunction

Project manager: I. Tarassov (I.Tarassov@unistra.fr)

UMR 7156 (GMGM):    teams N. Entelis & I. Tarassov; H. Becker              

UPR 2357 (IBMP):       teams L. Drouard; A. Dietrich; P. Giegé       

UPR 9002 (ARN):        team C. Florentz  & M. Sissler     

Visit the Homepage of MitoCross (http://mitocross.unistra.fr/)

     

 

 

Launching the new LIA: "ARN-MITOCURE"' 2012-2015

Our team participate in a new-born Laboratoire International Associé (LIA), acronyme ARN-mitocure, with the Moscow University.

The project aims to describe mechanisms of RNA targeting into mitochondria and to exploit this pathway to model gene therapy of mitochondrial pathologies.

Responsibles:

for the UMR 7156 - I. Tarassov;

for the Moscow University - I. Krasheninnikov.

Label "Equipe FRM 2008"

Our team was recently awarded by the Label "Equipe FRM", along with the financial aid of 261 k€, by Fondation pour la Recherche Médicale. The label was given at the ceremony which took place in Strasbourg, 29 June 2009. The representatives of the FRM congratulated Ivan Tarassov, directeur de recherche in the CNRS,  for the work on modeling of gene therapy of mitochondrial diseases. The ceremony was organized in presence of the local press, representatives of the CNRS, Strasbourg University, Mairie of Strasbourg and numerous Strasbourg's researchers.